Literature DB >> 34152808

Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital.

Emre Kara1, Gokhan Metan2, Aygin Bayraktar-Ekincioglu1, Dolunay Gulmez3, Sevtap Arikan-Akdagli3, Figen Demirkazik4, Murat Akova2, Serhat Unal2, Omrum Uzun2.   

Abstract

Antifungal stewardship (AFS) is recommended to reduce the inappropriate use of antifungal drugs. In this study, the role of AFS in providing appropriate antifungal therapy was evaluated. This study included three periods, consisting of observation, feedback/education, and daily AFS activities. In the observation period, the use of systemic antifungals was evaluated for a baseline measurement of appropriateness. In the second period, monthly meetings were organized to provide feedback and education to physicians regarding antifungal therapy and the rate of adherence to the clinical guidelines. In the final period, a clinical pharmacist participated in daily ward rounds to evaluate the appropriateness of the antifungal therapy. A scoring system for appropriateness was used for comparison between the three periods. Four hundred eighteen episodes of antifungal therapy were evaluated. Baseline demographics of patients were similar in all three periods for age, gender, and the number of comorbidities. The indications for antifungal use were for prophylaxis in 22.7%, Candida infections in 58.6%, and invasive mold infections in 18.7%. During the third period, 157 (78.9%) recommendations were made and 151 (96.2%) were accepted. The overall appropriateness of antifungal use increased significantly for prophylaxis (30.8%, 17.9%, and 46.3%; P = 0.046) and treatment of fungal diseases (27.8%, 32.4%, and 71.9%; P < 0.001) between the first, second, and third periods, respectively. The 30-day mortality was not significantly changed between the three periods (19%, 15.6%, and 27.5%; P = 0.050). Appropriateness in antifungal therapy can be augmented by the integration of an AFS program. A team-based evaluation of fungal infections and assessment of patients by a clinical pharmacist with a therapeutic perspective may help to increase the quality of antifungal therapy.

Entities:  

Keywords:  antifungal agents; antifungal therapy; pharmacology

Mesh:

Substances:

Year:  2021        PMID: 34152808      PMCID: PMC8370214          DOI: 10.1128/AAC.00629-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed.

Authors:  Maricela Valerio; Carmen Guadalupe Rodriguez-Gonzalez; Patricia Muñoz; Betsabe Caliz; Maria Sanjurjo; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2014-03-21       Impact factor: 5.790

2.  Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study.

Authors:  Apisada Sutepvarnon; Anucha Apisarnthanarak; Bernard Camins; Kristin Mondy; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254

3.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

4.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Authors:  A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely
Journal:  Clin Microbiol Infect       Date:  2018-03-12       Impact factor: 8.067

Review 5.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

Authors:  Johan A Maertens; Corrado Girmenia; Roger J Brüggemann; Rafael F Duarte; Christopher C Kibbler; Per Ljungman; Zdenek Racil; Patricia Ribaud; Monica A Slavin; Oliver A Cornely; J Peter Donnelly; Catherine Cordonnier
Journal:  J Antimicrob Chemother       Date:  2018-12-01       Impact factor: 5.790

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

7.  Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis.

Authors:  Hayato Mitaka; Toshiki Kuno; Hisato Takagi; Paru Patrawalla
Journal:  Mycoses       Date:  2021-05-06       Impact factor: 4.931

Review 8.  Risk factors for invasive fungal disease in critically ill adult patients: a systematic review.

Authors:  Hannah Muskett; Jason Shahin; Gavin Eyres; Sheila Harvey; Kathy Rowan; David Harrison
Journal:  Crit Care       Date:  2011-11-29       Impact factor: 9.097

9.  Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients.

Authors:  Koenraad H Vandewoude; Stijn I Blot; Pieter Depuydt; Dominique Benoit; Werner Temmerman; Francis Colardyn; Dirk Vogelaers
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

10.  Adherence to clinical practice guidelines for the treatment of candidemia at a Veterans Affairs Medical Center.

Authors:  Chester N Ashong; Andrew S Hunter; M David Mansouri; Richard M Cadle; Richard J Hamill; Daniel M Musher
Journal:  Int J Health Sci (Qassim)       Date:  2017 Jul-Sep
View more
  1 in total

1.  Public health issues with Candida auris in COVID-19 patients.

Authors:  Edmund J Janniger; Rajendra Kapila
Journal:  World Med Health Policy       Date:  2021-09-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.